What is IN8bio?
Founded in 2016 and headquartered in New York, IN8bio operates at the intersection of biotechnology and oncology. The company is dedicated to the discovery and development of next-generation cellular therapies, specifically focusing on allogeneic, autologous, and genetically modified gamma-delta T cells. By leveraging the unique properties of these cells, IN8bio aims to overcome the limitations of traditional cancer treatments, providing more precise and effective therapeutic options for patients. Their market position is defined by a robust intellectual property portfolio and a commitment to clinical excellence in the rapidly evolving field of immuno-oncology.
How much funding has IN8bio raised?
IN8bio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in IN8bio
PPP
Public-Private Partnership
What's next for IN8bio?
The infusion of capital from this major strategic investment will be instrumental in advancing IN8bio's clinical trials and expanding its manufacturing capabilities. As the company transitions into more advanced stages of development, the focus will likely shift toward scaling its proprietary cell-engineering processes and strengthening its regulatory pathway. Investors are closely monitoring the company's ability to translate its preclinical success into tangible clinical outcomes, which will be critical for future commercialization efforts and potential strategic partnerships within the broader biopharmaceutical landscape.
See full IN8bio company page
